Sugi Predict

Sugi Predict / Compounds / SCHEMBL1193264

SCHEMBL1193264

SCHEMBL1193264

Nc1nccc(Nc2ccccc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 15/20 1.00
▸ BCL6 P41182 1/20 1.00
▸ HTR3E A5X5Y0 1/20 0.66
▸ HTR3B O95264 1/20 0.66
▸ HTR3A P46098 1/20 0.66
▸ HTR3D Q70Z44 1/20 0.66
▸ HTR3C Q8WXA8 1/20 0.66
▸ PRKCD Q05655 2/20 0.65
▸ MAPT P10636 2/20 0.65
▸ RAB9A P51151 2/20 0.65
▸ CHEK1 O14757 1/20 0.65
▸ IKBKB O14920 1/20 0.65
▸ AURKA O14965 1/20 0.65
▸ NPC1 O15118 1/20 0.65
▸ PDPK1 O15530 1/20 0.65
▸ CHEK2 O96017 1/20 0.65
▸ PRKCG P05129 1/20 0.65
▸ CDK1 P06493 1/20 0.65
▸ LYN P07948 1/20 0.65
▸ KIT P10721 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12969353 0.83 ROCK1 (0.68) ROCK1BCL6HTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL15816794 0.82 ROCK1 (0.67) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL29645150 0.81 ROCK1 (0.69) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL31336991 0.81 ROCK1 (0.69) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL31337079 0.81 ROCK1 (0.69) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL13963140 0.81 ROCK1 (0.69) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL31337029 0.81 SCN9A (0.82) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL12813346 0.80 ROCK1 (1.00) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL27612768 0.80 SYK (0.70) ROCK1BCL6HTR3EHTR3BHTR3A
SCHEMBL29645155 0.80 ROCK1 (0.68) ROCK1BCL6HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486805-A 2-amino-4-phenylaminopyrimidine compound and application thereof 中国药科大学 2024-02-02 — — CN claimed
CN-121226335-B 2-Amino-4-anilinopyrimidine compound and preparation method and application thereof 中国药科大学 2026-03-20 — — CN disclosed
CN-121226335-B 2-Amino-4-anilinopyrimidine compound and preparation method and application thereof 中国药科大学 2026-03-20 — — CN disclosed
US-20260070921-A1 COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND UNIV KYOTO (JP) 2026-03-12 — — US disclosed
CN-121226335-A 2-Amino-4-anilinopyrimidine compound and preparation method and application thereof 中国药科大学 2025-12-30 — — CN disclosed
CN-121226335-A 2-Amino-4-anilinopyrimidine compound and preparation method and application thereof 中国药科大学 2025-12-30 — — CN disclosed
EP-4582430-A1 COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND Kyoto University (JP) 2025-07-09 — — EP disclosed
CN-119080704-A Rosin acid derivative and preparation method and application thereof 广东药科大学 2024-12-06 — — CN disclosed
CN-117486805-A 2-amino-4-phenylaminopyrimidine compound and application thereof 中国药科大学 2024-02-02 — — CN disclosed
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 — — EP disclosed
US-20030130289-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2003-07-10 — — US disclosed
EP-1317433-A2 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
US-6489344-B1 FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT CHIRON CORPORATION 2002-12-03 — — US disclosed
US-20020156087-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2002-10-24 — — US disclosed
US-6417185-B1 HETEROCYCLIC ENZYME INHIBITORS CHIRON CORPORATION 2002-07-09 — — US disclosed
WO-2002020495-A2 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2002-03-14 — — WO disclosed
CN-1312807-A Inhibitors of glycogen synthase kinase 3 CHIRON CORP (US) 2001-09-12 — — CN disclosed
EP-1087963-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 Chiron Corporation (US) 2001-04-04 — — EP disclosed
WO-1999065897-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 1999-12-23 — — WO disclosed
EP-0075242-A2 N-substituted 2,4-diamino-m-xylols and hair colouring compositions containing them Henkel Kommanditgesellschaft auf Aktien (DE) 1983-03-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070921-A1 COMPOUND, ENDOPLASMIC RETICULUM STRESS INHIBITOR, PHARMACEUTICAL PRODUCT, OPHTHALMIC AGENT, EYE DROPS, COMPOSITION, AND METHOD FOR PRODUCING COMPOUND XBP1, HSPA5, DNAJC10 ROCK1 731/4885BCL6 830/4885HTR3E 3705/4885
US-20030130289-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB ROCK1 255/4885BCL6 193/4885HTR3E 1859/4885
US-20020156087-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB ROCK1 255/4885BCL6 187/4885HTR3E 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.